Cantex Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Cantex Pharmaceuticals, Inc.
Aevi needs to raise funds first, but hopes to develop MEDI2338 for adult-onset Still’s disease. Also, Alnylam plans to leverage Ironwood’s GI expertise for givosiran in acute hepatic porphyria and Ultragenyx snags option to buy GeneTx.
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, New Drugs for Myocardial Infarction, features profiles of ArgiNOx Pharmaceuticals, ParinGenix and VasoGenix Pharmaceuticals. Plus these Start-Ups Across Health Care: AngioScore, Hamilton Pharmaceuticals, Ikaria, Light BioScience and Potentia Pharmaceuticals.
ParinGenix Inc. is currently developing a modified form of the widely used anticoagulant, heparin, to treat cardiac ischemia-reperfusion injury following myocardial infarction.
Ischemia-induced damage isn't the only harmful effect of heart attacks, and a number of recently founded companies are investigating new mechanisms to protect the heart.
- Synthesis Technologies, Production Processes